The Half-Truth of the “Accident”
Few phrases are repeated as often in the history of psychopharmacology as the claim that LSD was an accidental finding. It is a comfortable image: the absent-minded chemist, the falling drop, the bicycle. But Albert Hofmann himself took care to qualify it. The substance, he wrote, was born “in the course of systematic investigation,” and the famous accident arrived much later. When in 1943 he felt its effects for the first time, the molecule was already five years old and lay archived in a drawer.
This installment—seventh in our series dedicated to Hofmann—focuses precisely on that less-told period: the laboratory years that preceded the celebrated episode. It is the sober part of the story, the one explaining why LSD could exist before anyone suspected what it was good for.
A Chemist Who Preferred the Natural
In the spring of 1929, having just finished his studies at the University of Zurich, Hofmann entered the chemical-pharmaceutical laboratory of Sandoz in Basel as an assistant to Arthur Stoll, founder and director of the department. He had two other job offers from the Basel chemical industry, but turned them down: they involved working with synthetic products, and he was interested in natural substances.
That inclination had deep roots. His doctoral dissertation, directed by Paul Karrer, had addressed the enzymatic degradation of chitin—the material forming the shells, wings, and claws of insects and crustaceans—using the gastrointestinal juice of the vineyard snail. The work revealed that chitin was an analogue of plant cellulose and earned him a cum laude obtained in barely three months. That taste for organic chemistry of biological origin would shape his entire career.
From Squill to Ergot
Stoll’s department pursued a concrete goal: to isolate the active principles of known medicinal plants in pure, stable form. The problem with many of those botanical drugs—foxglove (Digitalis), sea squill (Scilla maritima), rye ergot (Secale cornutum)—was their instability: without a purified and quantifiable active ingredient, dosing them safely was almost impossible. Chemistry in the service of pharmacy, in short.
Hofmann’s first years at Sandoz were spent almost entirely among squill glycosides. His most notable contribution was clarifying the structure of the shared nucleus of those compounds, showing both their differences from digitalis glycosides and their striking kinship with toxins found in the skin glands of toads. Around 1935 that project came to a close, and the chemist sought new ground.
He found it in ergot, a field Stoll had explored in 1917 and set aside after isolating ergotamine in 1918—the first ergot alkaloid obtained in a chemically pure state, marketed as Gynergen for obstetric hemorrhages and migraines. By the early 1930s, British and American laboratories were beginning to unravel the structure of these alkaloids. Resuming research was, for Sandoz, a matter of not falling behind. Stoll agreed, though not without cautioning his assistant: these were delicate substances that decomposed easily. Hofmann would later recall the anticipated pleasure of venturing into such untrodden territory.
1938: Molecule Number Twenty-Five
Lysergic acid, the common foundation of ergot alkaloids, proved as unstable as Stoll had anticipated. Even so, Hofmann steadily obtained a series of derivatives. The twenty-fifth in that series was lysergic acid diethylamide—LSD-25 for short—synthesized for the first time in 1938.
The intention was anything but visionary: he sought a circulatory and respiratory stimulant, an analeptic, by structural analogy with nicotinic acid diethylamide (Coramine), which was then used for that purpose. In tests conducted by Sandoz’s pharmacological department, headed by Ernst Rothlin, LSD-25 exhibited potent uterotonic action and left test animals remarkably restless. But it did not arouse sufficient interest among pharmacologists and physicians, and it was shelved. Over the following five years, while Hofmann advanced on other ergot fronts—preparing drugs such as Methergine, Hydergine, or Dihydergot for clinical trials and production—the molecule that would transform twentieth-century psychiatry remained forgotten.
Where This Account Comes From
The testimony summarized here comes from an essay by Hofmann titled How LSD originated, published in 1979 in the Journal of Psychedelic Drugs and closely related to the material in his autobiography, LSD. Mein Sorgenkind (published in Spanish as LSD. Cómo descubrí el ácido y qué pasó después en el mundo). The English version was translated by Jonathan Ott, a central figure in ethnobotany and entheogenics, whom Hofmann personally entrusted with the task due to his dual background as a chemist and connoisseur of entheogens.
The small publishing history reveals the apprehensions of that era: McGraw-Hill went as far as printing the English edition and then refused to distribute it because the subject made its executives uncomfortable. Hofmann and Ott rescued the copies by buying them and reclaiming the publishing rights. As for the journal, it had been founded by David E. Smith in 1967 alongside the Haight Ashbury Free Clinics in San Francisco—providing free medical care to youths struggling with drug problems during the hippie heyday; it would later be renamed the Journal of Psychoactive Drugs.
Critical Reading
This account should be read with two cautions. The first is that it is an autobiographical testimony, written decades after the events and by the central protagonist himself: it arranges the past with the coherence afforded by knowing the ultimate outcome. The phrase “it was not entirely an accident” is true, but it is also the phrasing of someone seeking to assert the rigor of his work against legend. Historians of science frequently note that nearly every discovery combines method and chance in proportions that are difficult to untangle.
The second caution concerns context. This is a chapter in industrial pharmaceutical chemistry, not an instructional guide: there are no synthesis procedures or doses here, and we deliberately omit them. The value of the story lies in understanding how a molecule conceived to stimulate respiration ended up, years later, transformed into a tool for exploring the human mind—and eventually into a cultural phenomenon and public health issue. That gap between a chemist’s original intent and the uses society finds for a compound is perhaps the most enduring lesson of the entire episode.
